Feit K - Search Results

1

A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.

Abou-Alfa GK, Rowinsky EK, Patt YZ, Schwartz GK, Kelsen DP, Sharma S, Siegel E, Becerra CR, Eckhardt SG, Feit K, De Jager R, O'Reilly EM. Abou-Alfa GK, et al. Among authors: feit k. Am J Clin Oncol. 2005 Aug;28(4):334-9. doi: 10.1097/01.coc.0000158829.63542.2c. Am J Clin Oncol. 2005. PMID: 16062073 Clinical Trial.

2

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Abou-Alfa GK, et al. Among authors: feit k. J Clin Oncol. 2006 Sep 20;24(27):4441-7. doi: 10.1200/JCO.2006.07.0201. J Clin Oncol. 2006. PMID: 16983112 Clinical Trial.

3

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.

Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. Ajani JA, et al. Among authors: feit k. Invest New Drugs. 2005 Oct;23(5):479-84. doi: 10.1007/s10637-005-2907-z. Invest New Drugs. 2005. PMID: 16133799 Clinical Trial.

4

Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.

Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S. Patel S, et al. Among authors: feit k. Cancer. 2006 Dec 15;107(12):2881-7. doi: 10.1002/cncr.22334. Cancer. 2006. PMID: 17109446 Free article. Clinical Trial.

5

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. Riely GJ, et al. Among authors: feit k. Lung Cancer. 2007 Feb;55(2):181-5. doi: 10.1016/j.lungcan.2006.10.002. Epub 2006 Nov 7. Lung Cancer. 2007. PMID: 17092603 Clinical Trial.

6

Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.

Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM. Goldberg JS, et al. Among authors: feit k. Cancer. 2002 Sep 15;95(6):1220-7. doi: 10.1002/cncr.10809. Cancer. 2002. PMID: 12216088 Free article. Clinical Trial.

7

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP. de Bono JS, et al. Among authors: feit k. Ann Oncol. 2012 May;23(5):1241-1249. doi: 10.1093/annonc/mdr380. Epub 2011 Sep 7. Ann Oncol. 2012. PMID: 21903605 Free article. Clinical Trial.

8

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.

Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A, Verbel DA, Von Hoff DD. Tibes R, et al. Among authors: feit k. Br J Cancer. 2018 Jun;118(12):1580-1585. doi: 10.1038/s41416-018-0099-5. Epub 2018 Jun 5. Br J Cancer. 2018. PMID: 29867224 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters